Skip to main content
Premium Trial:

Request an Annual Quote

European Regulators Clear Danaher Purchase of Beckman Coulter

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher's pending $6.8 billion purchase of Beckman Coulter has cleared the last regulatory hurdle, the Washington-based conglomerate announced after the close of the market Thursday.

The European Commission approved the deal, paving the way for the acquisition to close. Danaher's tender offer to acquire all outstanding shares of Beckman Coulter stock at $83.50 per share is scheduled to expire at 5 p.m. EDT, June 24. It reiterated that the deal is expected to be completed by the end of the month. The US Federal Trade Commission cleared the purchase in March.

Earlier this week, Danaher announced a public offering at $51.75 per share to raise as much as $965.3 million in net proceeds if underwriters on the offering exercise their over-allotment option in full. Net proceeds will be used to pay a portion of the acquisition. Proceeds also may be used for general corporate purposes, if there are any remaining from the offering or if the Beckman deal fails to close.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.